Odyssey Therapeutics, Inc. (ODTX)

Odyssey Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	41.69	59.14
Short-Term Investments	139.67	70.22
Cash & Cash Equivalents	181.36	129.35
Cash Growth	40.20%	-
Other Current Assets	9.3	6.16
Total Current Assets	190.66	135.51
Property, Plant & Equipment	7.21	12.1
Long-Term Investments	35.2	-
Goodwill and Intangibles	33.39	41.28
Other Long-Term Assets	3.33	8.54
Total Long-Term Assets	79.13	61.93
Total Assets	269.79	197.44
Accounts Payable	7.87	6.32
Current Debt	5.21	4.58
Other Current Liabilities	13.39	17.52
Total Current Liabilities	26.48	28.42
Long-Term Debt	21.9	26.43
Other Long-Term Liabilities	6.13	10.22
Total Long-Term Liabilities	28.03	36.65
Total Liabilities	54.51	65.07
Total Debt	27.11	31.01
Debt Growth	-12.56%	-
Retained Earnings	-568.14	-419.49
Comprehensive Income	0.25	-1.34
Shareholders' Equity	-488.28	-382.53
Net Cash (Debt)	154.25	98.35
Net Cash (Debt) Growth	56.84%	-
Working Capital	164.18	107.1

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).